摘要
去唾液酸糖蛋白受体(asialoglycoprotein receptor,ASGPR)是一种主要表达在肝窦状隙和基底外侧细胞表面的受体,它能专一性识别、结合并内吞末端具有半乳糖或乙酰氨基半乳糖残基的去唾液酸糖蛋白类物质。基于这一特性,ASGPR受体介导的肝肿瘤靶向治疗引起了研究者们的广泛关注。本文从糖基化前药、小分子纳米药物载体和糖基化基因复合物3个方面对近3年来该领域的最新研究进展进行综述。
Asialoglycoprotein receptor (ASGPR) is a receptor expressed mainly on the surface of liver sinusoidal and basolateral cells. It can exclusively identity, combine and clear desialylated glycoproteins with exposed non-reducing D-galactose (Gal) or nacetylgalactosamine (GalNAc) as end groups. Based on this characteristic, ASGPR-mediated targeted liver cancer therapy has drawn extensive attention. The present review details the latest research progress of this field in three aspects, glycosylated prodrug, small molecular nanocarriers, and glycosylated gene complex therapy system.
作者
高媛悦
刘爱赟
沈佳佳
丁娅
GAO Yuanyue LIU Aiyun SHEN Jiajia DING Ya(Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing 210009, China)
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2016年第5期537-542,共6页
Journal of China Pharmaceutical University
基金
国家自然科学基金资助项目(No.31470916
No.31500769)
药物质量与安全预警教育部重点实验室开放课题资助项目(No.DQCP2015MS01)~~
关键词
去唾液酸糖蛋白受体
肝靶向
前药
药物载体
基因治疗
asialoglycoprotein receptor
targeted liver cancer therapy
prodrug
drug carrier
gene therapy